Showing results (1-10 of 690) with videos related to
Sort By:
Pageof 69
Clinical Pharmacology and Therapeutics|November 14, 1997
Induction of CYP2D6 in pregnancyM Wadelius, E Darj, G Frenne, et al.Pharmacogenetics|September 2, 1999
Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancerM Wadelius, J L Autrup, M J Stubbins, et al.Pharmacogenetics|March 30, 2000
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosisM Wadelius, E Stjernberg, B E Wiholm, et al.Pharmacogenetics|December 11, 1999
Prostate cancer associated with CYP17 genotypeM Wadelius, A O Andersson, J E Johansson, et al.Human & Experimental Toxicology|May 16, 2008
Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placentaM Rahi, T Heikkinen, J Hakkola, et al.The Pharmacogenomics Journal|December 17, 2003
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsM Wadelius, K Sörlin, O Wallerman, et al.Journal of Medical Genetics|October 10, 1997
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazidC A Smith, M Wadelius, A C Gough, et al.The Pharmacogenomics Journal|May 11, 2005
Common VKORC1 and GGCX polymorphisms associated with warfarin doseM Wadelius, L Y Chen, K Downes, et al.Clinical Pharmacology and Therapeutics|April 23, 2010
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and ageA-K Hamberg, M Wadelius, J D Lindh, et al.The Pharmacogenomics Journal|September 20, 2006
Pharmacogenetics of warfarin: current status and future challengesM Wadelius, M PirmohamedPageof 69